Investing in
breakthrough technologies
PHILOSOPHY
Investing in our beliefs of a technology— enabled world
Identifying opportunity and investing in the potential of growth and progress is at the heart of our investment approach.
Focusing on late-stage, pre-IPO financing rounds, our investments aim to capture the sweet spot of turning risk to reward.
ABOUT
Venture arm of Infinitas Capital
By leveraging our existing ties with leading family offices and hedge funds, we are able to gain access to exclusive and rewarding opportunities.
We enable our investors to co-invest alongside us in our most exciting opportunities
Portfolio
News
News
Alto Neuroscience emerges from stealth
Alto is bringing EEG-based and AI-identified biomarkers to psychiatry to develop precision medicine for the brain.
Rejuveron Life Sciences will acquire majority shareholding in Rejuvenate Biomed
The funding is being used to accelerate the clinical development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia (disuse-induced and age-related muscle failure).
Wonder Brands-picks up 20m - aims to build marketplace of latin american-e-commerce brands
Wonder Brands closed on $20 million in seed funding, co-led by ALLVP and Mountain Nazca, with participation from CoVenture, Victory Park Capital, GFC, QED (Fontes), Korify Capital, and Endeavor Catalyst.
atai x Revixia Life Sciences
atai Life Sciences announced the launch of Revixia Life Sciences, a wholly owned subsidiary developing Salvinorin A to treat a variety of mental health disorders.
atai x InnarisBio Inc.
atai Life Sciences and UniQuest, Australia’s leading university technology transfer company commercializing the research of The University of Queensland (UQ), today announced the launch of InnarisBio Inc. (InnarisBio), to develop a novel sol-gel intranasal drug delivery technology.
Bullish SPAC Merger
Crypto exchange Bullish will merge with SPAC Far Peak Acquisition Corporation and list on the NYSE by the end of the year, per Business Wire.
We're hiring
Fasten your seatbelt and prepare for takeoff 🚀🚀
Please contact Sarah Koelman at [email protected]
Update Recognify Life Sciences
Recognify Life Sciences to Commence Phase 2a Study in Cognitive Impairment Associated with Schizophrenia.
Update Perception Neuroscience <> Otsuka Pharmaceutical
Perception Neuroscience And Otsuka Pharmaceutical Announce Collaboration On Development Of PCN-101 (R-ketamine) In Japan For Treatment-of Depressive Disorders.
Korify Capital - LinkedIN
Korify Capital invests in breakthrough technologies.
CONTACT
If you are interested in learning more about Korify Capital, let us know.
I am a